A University of Connecticut researcher and his team have discovered that a species of tiny aquatic organism prominent in harmful algal blooms sometimes called "red tide" is even deadlier than first thought, with potential consequences for entire marine food chains.

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.